to-BBB, the brain drug delivery company, is pleased to announce the successful completion of its 2B3-101 Phase I part of its clinical trial in brain cancer patients, safely reaching clinically effective dosages. to-BBB is now ready to proceed to the Phase IIa part of this trial, treating patients with brain metastases from breast cancer, small cell lung cancer and melanomas, as well as patients with primary, malignant brain cancers (recurrent gliomas)...
More...
More...